Skip to main content

What Edwards Lifesciences's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Edwards Lifesciences filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses compliance burden, goodwill impairment and product launch.

Public (EW)Medical Equipment Manufacturing10,000+ employeesedwards.comLinkedIn

Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API

AskWhat changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.
Filed
Nov 4, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
12

Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated

10-Q · latest 10

What Edwards Lifesciences's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 4 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 4 signals

    SEC EDGAR

Showing 10 of 12 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Edwards Lifesciences earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Q3 sales rise 11.2% to $1.72B with 78.7% gross marginThird quarter sales reached $1.72 billion representing 11.2% year-over-year underlying growth, while adjusted gross profit margin expanded to 78.7% from 77.9%. Operating profit margin achieved 30.3% and adjusted EPS reached $0.80. The company's performance signals strong cash generation and budget capacity for commercial and operational vendors.
Full-year sales growth raised to 11.5% and EPS to $3.01Management raised full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS to $2.97-$3.05 (midpoint $3.01, representing 18% growth). TAVR full-year guidance was raised to 9%-9.5% and TMTT expectations increased to $780M-$790M. Expanding operational and commercial budgets will support these upgraded delivery targets.
TAVR global sales grow 8.8% to $1.2B in third quarterGlobal TAVR procedure growth drove revenue of $1.2 billion, up 8.8% year-over-year with balanced performance across the U.S. and OUS markets. ASPs remained stable globally while procedure volumes accelerated exiting the quarter. Sales teams targeting cath lab workflows and structural heart infrastructure can capitalize on continuing procedural volume expansion.
Annualized Boston Scientific European exit while stabilizing TAVR shareEdwards noted that benefits from Boston Scientific's European exit have annualized after four quarters of share gains. Going forward, management expects TAVR growth to rely primarily on market procedure volume rather than market share expansion against competitors.
TAVR market share gains plateau after Boston Scientific exitThe company marked over four consecutive quarters of modest TAVR share gains following Boston Scientific's May 2025 exit from Europe and OUS markets. While sequential share has now stabilized, future growth will tilt toward underlying market procedure volume expansion and expanded indications rather than further competitor displacement. Vendors helping optimize patient intake and clinical...
Five structural heart therapy approvals expand portfolio commercializationThe company secured 5 therapy approvals over recent months, including U.S. approvals for PASCAL Ace with Capture Clarity, PASCAL Precision for tricuspid regurgitation, and pediatric pulmonary valve AUTUS. Commercial teams are executing major rollouts for Capture Clarity and ECLIPTIS while expanding EVOQUE transjugular access in the U.S. and Europe. These commercial introductions require...

Signal API · MCP

Track Edwards Lifesciences with the Signal API

One POST /v1/companies/enrich call with edwards.com returns Edwards Lifesciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"edwards.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Edwards Lifesciences 10-Q

When did Edwards Lifesciences file its latest 10-Q?
Edwards Lifesciences filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 4, 2026. The one before it was filed on Aug 4, 2026.
What did Edwards Lifesciences disclose in its latest 10-Q?
From the filing dated Nov 4, 2026: Edwards Lifesciences records $220.2 million impairment on in-process R&D intangible asset
What did Edwards Lifesciences say on its recent earnings calls?
Q3 FY2026: Q3 sales rise 11.2% to $1.72B with 78.7% gross margin (dated Nov 4, 2026).
Where can I read Edwards Lifesciences's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000054/ew-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →